Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price dropped 14.3% during trading on Wednesday . The company traded as low as C$0.06 and last traded at C$0.06. Approximately 140,000 shares changed hands during mid-day trading, an increase of 44% from the average daily volume of 97,516 shares. The stock had previously closed at C$0.07.
Hemostemix Stock Down 14.3 %
The company has a market cap of C$5.23 million, a P/E ratio of -3.50 and a beta of 0.20. The firm has a fifty day moving average price of C$0.08 and a 200 day moving average price of C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- 3 Warren Buffett Stocks to Buy Now
- The Great CPU Race: AMD and Intel Battle for Dominance
- How to Most Effectively Use the MarketBeat Earnings Screener
- GameStop Turns a Profit: So What? It’s Still Not Worth Investing
- Low PE Growth Stocks: Unlocking Investment Opportunities
- C3.ai Stock Surges on Strong Sales Despite Profit Concerns
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
